Bipolar disorder was previously known as manic depression. It is a form of major affective, or mood disorder, which is defined by manic or hypomanic episodes (changes from one's normal mood accompanied by high energy states). Bipolar disorder is a complex disorder that likely stems from a combination of genetic and non-genetic factors. The condition may not be the same for every person who has it. Certain people may experience mostly depressed states, and other people may experience mostly manic phases. There is also the possibility of having both depressed and manic symptoms simultaneously.
There are three recognized types of bipolar disorder: Type I, Type II, and Type III. Bipolar disorder commonly appears after 24 and continues throughout a person’s lifetime. It is rare that newly diagnosed mania is seen in young children or adults over age 65. And according to the National Institute of Mental Health, it is estimated that approximately 5.7 million adult Americans, or about 2.6% of the US population aged 18 and above each year. There is a 2.5% chance of developing bipolar disorder type I & II during your lifetime in Australia. No racial differences exist. Males are more likely to develop bipolar disorder than females.
This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation by Status
8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence